Condition: Systemic Sclerosis (SSc) · Sponsor: argenx
The main purpose of this study is to evaluate the effect and safety of efgartigimod PH20 SC compared to placebo in adults with systemic sclerosis. The study consists of a screening period, a treatment period of up to 48 weeks and a safety follow-up period. After the screening period, eligible participants will be randomized in a 2:1 ratio to receive either efgartigimod PH20 SC or placebo. The total study duration can be up to approximately 15 months. More information can be found on: https://clinicaltrials.argenx.com/esscape
This description comes directly from the study's public registry record.
Sabine Coppieters, MD · 857-350-4834 · clinicaltrials@argenx.com
Always discuss trial participation with your own doctor first.
| Arizona Arthritis and Rheumatology Associates | Phoenix, Arizona, United States | Recruiting |
| UCLA Ronald Reagan University of California Los Angeles Medical Center | Los Angeles, California, United States | Recruiting |
| IRIS Research and Development LLC | Plantation, Florida, United States | Recruiting |
| University of Illinois Health Outpatient Care Center | Chicago, Illinois, United States | Recruiting |
| DelRicht Research, LLC | New Orleans, Louisiana, United States | Recruiting |
| Johns Hopkins Asthma and Allergy Center | Baltimore, Maryland, United States | Recruiting |
| Thomas Jefferson University | Columbia, Maryland, United States | Recruiting |
| University of Michigan Hospital | Ann Arbor, Michigan, United States | Recruiting |
| Perelman Center for Advanced Medicine | Philadelphia, Pennsylvania, United States | Recruiting |
| Aprillus Asistencia e Investigacion | Buenos Aires, Argentina | Recruiting |
| Instituto de Investigación Clínica TyT | Buenos Aires, Argentina | Recruiting |
| Consultorios Médicos Dr. Doreski - Fundacion Respirar | Buenos Aires, Argentina | Recruiting |
+ 64 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06655155